Granules India Ltd News
RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead
The heavy-weight Reliance Industries has broken critical support of Rs 2,300, raising concerns about the future drawdown. In addition, the formation reveals a "Descending Triangle" violation
 "RIL, Mphasis: 45 stocks hit fresh 52-week lows; charts show more pain ahead")
Granules gets USFDA nod to market generic medicine for high blood pressure
Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic product to treat high blood pressure. The company has received approval from the US Food & Drug Administration (USFDA) to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing. The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets. According to IQVIA/IMS Health, the current annual US market for Losartan potassium tablets is around USD 336 million. Shares of the company were trading 1.24 per cent down at Rs 281.75 apiece on the BSE.
 "Granules gets USFDA nod to market generic medicine for high blood pressure")
Granules forges strategic partnership with Greenko ZeroC for Kakinada plant
Under the collaboration, Greenko ZeroC will be supplying carbon free energy and enable green hydrogen along with its various chemical derivatives
Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%
Technically, the Nifty Pharma index needs to immediate hurdle at 13,500, for further upside to 14,250.
 "Pharma stocks upbeat amid Covid-19 scare; Divi's, Lupin can gain up to 10%")
